Buscar resultados de ensayos clínicos
Lymphoma, T-Cell - 77 Studies Found
Estado | Estudiar |
Recruiting |
Nombre del estudio: Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma Condición:
|
Terminated |
Nombre del estudio: CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell Lymphoma Condición: T-cell Lymphoma Fecha: 2009-05-05 Intervenciones:
|
Not yet recruiting |
Nombre del estudio: Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients Condición: Peripheral T Cell Lymphoma Fecha: 2016-11-03 Intervenciones:
|
Recruiting |
Nombre del estudio: Endostar Aggressive Treatment of Peripheral T-cell Lymphoma (PTCL) Phase II Clinical Study Condición: Peripheral T-cell Lymphomas Fecha: 2015-07-26 Intervenciones:
|
Recruiting |
Nombre del estudio: Open-label Pilot Study of Lenalidomide (Revlimid) as Adjuvant Treatment for Refractory Cutaneous T Cell Lymphoma Condición: Cutaneous T Cell Lymphoma Fecha: 2010-05-25 Intervenciones: Drug: Lenalidomide Lenalidomide Starting Dose Based on Renal Function at Study Entry Baseline Calculated |
Completed |
Nombre del estudio: Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL) Condición: Lymphoma, T-Cell, Cutaneous Fecha: 2011-09-09 Intervenciones:
|
Completed |
Nombre del estudio: A Study of the Histone Deacetylase Inhibitor (HDACi) Quisinostat (JNJ-26481585) in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma Condición: Lymphoma, T-Cell, Cutaneous Fecha: 2011-11-29 Intervenciones: Drug: Quisinostat, 12 mg Participants will receive quisinostat 12 mg capsule orally (by mouth) on Days 1 |
Completed |
Nombre del estudio: CPG 7909 in Patients With Cutaneous T-Cell Lymphoma Condición: Lymphoma, T-Cell, Cutaneous Fecha: 2002-08-08 Intervenciones:
|
Completed |
Nombre del estudio: Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL) Condición: Lymphoma, T-Cell, Cutaneous Fecha: 2005-09-13 Intervenciones: Drug: ONTAK (denileukin difitox, DAB389IL-2) |
No longer available |
Nombre del estudio: Compassionate Use of Vorinostat for the Treatment of Patients With Advanced Cutaneous T-Cell Lymphoma (0683-042) Condición: Lymphoma, T-Cell, Cutaneous Fecha: 2007-01-05 Intervenciones: Drug: Comparator: vorinostat Each patient will receive open-label vorinostat 400 mg q.d. capsules. Treat |